Pharmaceutical Executive Europe - November 2008 - (Page 3)

EDITORIAL ADVISORY BOARD Pharmaceutical Executive Europe’s Editorial Advisory Board (EAB) is a distinguished group of specialists who represent various facets of the pharmaceutical industry. EAB members suggest article subjects relevant to the industry, review article manuscripts, participate in events and answer questions as they arise. Change is coming S o, the US has voted to swing to the left (left of George Bush, that is) and put Barack Obama into the White House. I don’t need to go on about how historic this is; needless to say, the animated discussions, celebrations and commiserations will be going strong well into next month. But a question we can consider is what does it mean for pharma and healthcare? Obama has certainly put his cards on the table when it comes to stem cell research, an area that has so far been held back in the US by President Bush’s ‘moralistic’ concerns. Obama has pledged not only to lift the restrictions currently hampering stem cell research, but to double budgets for “high-risk, high-payoff research.” But his plans for Big Pharma are a little more stern. He has made noises about Medicair adopting a UK NICE-style approach to fixing drug prices with the pharma giants — something that could take a huge chunk out of the industry’s US earnings — and about encouraging the widespread use of generics. With a hefty amount support behind him, it would seem that Obama’s talk of change could turn into action. But we’ve seen before that ‘radical’ healthcare plans can get shot down in the US, whoever is in office. Of only slightly less worldwide significance is the change that is coming to Pharm Exec Europe. Those of you who have followed the magazine’s evolution will know that we are no stranger to the word ‘change’ ourselves. But I hope you will welcome our plans to provide you with more regular news and features from January 2009. I’ll be telling you more about this in next month’s issue. Pharmaceutical Executive Europe provides industry intelligence so managers in the European pharmaceutical community can advance their business, management and marketing practices to gain competitive advantage. PEE interprets the current and future challenges the industry faces and enables pharmaceutical professionals to overcome them with cost-effective, time-saving solutions. Branding Rebecca Robins Global Marketing Director Interbrand Healthcare Business/Marketing Keith Allan Head of Global Product Advocacy Novartis Pharma Clinical Trials Nathan Waller Director, Account Management PAREXEL International Patient Communications Nick Hicks Director,Commutateur Executive/Strategy David Barratt CEO Euro RSCG Life UK Dr Brian D. Smith Visting Fellow, Open University and CEO, Pragmedic Supply Chain Julian Mount Senior Director Head of European Trade, Pfizer Biopartnering Gerhard Symons Doctoral Researcher Imperial College Business School, London Medical Education Peter George CEO, Penn Pharmaceutical Services Information Technology George Laszlo Managing Director Laszlo Consulting Group Publisher Andy Davies Tel. +44 1244 393 408 adavies@advanstar.com Editorial Director Peter Houston Tel. +44 1244 393 435 phouston@advanstar.com Editor Julian Upton jupton@advanstar.com Sales Manager James Gray jgray@advanstar.com Marketing Manager Sally Carron scarron@advanstar.com Sales Support Claire Rice crice@advanstar.com Senior Designer Ian Williams iwilliams@advanstar.com Chief Executive Officer Joe Loggia VP, Chief Financial Officer Ted Alpert VP, Corporate Development Eric I. Lisman VP, Market Development, Europe & Licensing Group Georgiann DeCenzo VP, Life Sciences Group Steve Morris VP, Media Operations Francis Heid VP, Information Technology J Vaughn VP, Electronic Media Group Mike Alic VP, Human Resources Nancy Nugent VP, Treasurer & Controller Shelbie O’Brien VP, General Counsel Ward D. Hewins Advanstar Communications (U.K.) Ltd Corporate Office 6200 Canoga Ave, 2nd Floor Woodland Hills CA 91367 Subscribe online at www.pharmexeceurope.com Pharmaceutical Executive Europe is free to qualified subscribers in Europe. To apply for a free subscription, or to change your name or address, go to www.pharmexeceurope.com, click on Subscribe, & follow the prompts. To cancel your subscription or to order back issues, please email your request to magazines@superfill.com, putting PEE in the subject line. Please quote your subscription number if you have it 1 year (8 issues) 2 years (16 issues) Non-qualified readers in Europe £100 £170 Current issue: £20 Readers outside Europe £140 £240 Back issue: £35 Copyright ©2008. Advanstar Communications (UK) Ltd. All rights reserved. No part of this publication may be reproduced in any material form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner except in accordance with the provisions of the Copyright, Designs & Patents Act (UK) 1988 or under the terms of a licence issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP, UK. Julian Upton jupton@advanstar.com Applications for the copyright owner’s permission to reproduce any part of this publication should be forwarded in writing to Permissions Dept, Advanstar Communications (UK) Ltd, Advanstar House, Park West, Sealand Road, Chester CH1 4RN, UK. Warning: The doing of an unauthorized act in relation to a copyright work may result in both a civil claim for damages and criminal prosecution. 4 News Round-up The month in pharma 7 Calendar December’s industry events 8 Reflector Parallel traders off the hook 9 Strategy Fundamentals Understanding Ansoff’s Matrix http://www.pharmexeceurope.com http://www.pharmexeceurope.com

Table of Contents for the Digital Edition of Pharmaceutical Executive Europe - November 2008

Pharmaceutical Executive Europe - November 2008
Contents
From the Editor
News Round-Up
Calendar
Brussels Report
Using the Wooden Spoon
VC: Virtuous or Vampire Capital?
Is Pharma Recession-Proof?
Servier: Patience and Passion
Boost Your Brain Power
Innovation, Innovation, Innovation
Last Words

Pharmaceutical Executive Europe - November 2008